SCHEMBL4922277

SCHEMBL4922277

CCOC(=O)c1ccc(NC(=O)Nc2nc(C)c(C(=O)OCC)s2)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.80
ALDH1A1 P00352 8/20 0.80
NPC1 O15118 7/20 0.80
RAB9A P51151 5/20 0.80
HPGD P15428 5/20 0.80
MAPT P10636 5/20 0.80
MEN1 O00255 4/20 0.80
KMT2A Q03164 4/20 0.80
HTT P42858 2/20 0.80
GAA P10253 2/20 0.80
NFKB1 P19838 1/20 0.80
NFKB2 Q00653 1/20 0.80
RELA Q04206 1/20 0.80
RXFP1 Q9HBX9 3/20 0.64
NPSR1 Q6W5P4 3/20 0.64
KDM4E B2RXH2 7/20 0.62
LMNA P02545 3/20 0.60
DHODH Q02127 2/20 0.60
CASP3 P42574 1/20 0.59
TRPV1 Q8NER1 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5176803 0.92 NPC1 (0.70) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL4913550 0.89 SMN1; SMN2 (1.00) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL4920930 0.89 SMN1; SMN2 (0.78) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL5176202 0.89 KMT2A (0.74) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL5174406 0.87 KMT2A (0.78) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL4921346 0.87 SMN1; SMN2 (0.76) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL774511 0.85 LCK (0.71) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL16607174 0.83 ALDH1A1 (0.75) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL4917050 0.81 SMN1; SMN2 (0.76) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL7147053 0.80 ALDH1A1 (0.74) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP disclosed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R SMN1; SMN2 3931/4885ALDH1A1 274/4885NPC1 148/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R SMN1; SMN2 3931/4885ALDH1A1 274/4885NPC1 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.